Loading...
Please wait, while we are loading the content...
Essence of survival analysis†.
| Content Provider | Europe PMC |
|---|---|
| Author | Pugh, Stephanie L. |
| Copyright Year | 2016 |
| Abstract | Abstract Many clinical trials are designed based on a time-to-event endpoint. Overall survival and progression-free survival are commonly used, especially in Phase II and III clinical trials. Overall survival measures the time to death from any cause, while progression-free survival measures the time to progression of the disease or death from any cause. The key distinguishing factor is that the event of interest, such as death, may not occur in all individuals, making their time to this event unknown. Survival analysis comprises of the methods used to estimate the rates associated with time-to-an-event data, compare the rates between groups, and assess how other factors impact these rates. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6655525&blobtype=pdf |
| Page Count | 5 |
| ISSN | 20542577 |
| Volume Number | 4 |
| DOI | 10.1093/nop/npw012 |
| PubMed Central reference number | PMC6655525 |
| Issue Number | 2 |
| PubMed reference number | 31386005 |
| Journal | Neuro-Oncology Practice [Neurooncol Pract] |
| e-ISSN | 20542585 |
| Language | English |
| Publisher | Oxford University Press |
| Publisher Date | 2016-12-09 |
| Publisher Place | US |
| Access Restriction | Open |
| Rights License | © The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Subject Keyword | log-rank test survival analysis time to event |
| Content Type | Text |
| Resource Type | Article |
| Subject | Neurology Medicine Oncology |
